2008: RA Treatment: Biologic Efficacy RCT's
Search or Browse by Day

RA Treatment: Biologic Efficacy RCT's

Monday, October 27, 2008
1208
Clinical Remission, Radiographic Non-progression, and Normalized Function With the Combination of Etanercept and Methotrexate in the Treatment of Early Active Rheumatoid Arthritis: 1-year Results of the COMET Trial
1209
Tociluzumab (TCZ) Rapidly and Significantly Improves Outcomes in Patients with Rheumatoid Arthritis (RA) Who Have Inadequate Response (IR) to TNF Antagonists
1210
The AMBITION Study: Superiority of Tociluzumab (TCZ) vs Methotrexate (MTX) Monotherapy in Patients with Rheumatoid Arthritis (RA)
1211
Golimumab Administered Subcutaneously Every 4 Wks in Patients with Active Rheumatoid Arthritis Despite Methotrexate: Wk 24 Results of the Randomized, Double-Blind, Placebo-Controlled, GO-FORWARD Study
1212
Efficacy, Safety, And Dose Frequency Of Retreatment With Rituximab In RA: Results From A Randomized Controlled Trial (SUNRISE)
1213
The Efficacy and Safety of Abatacept in Methotrexate-naïve Patients with Early Erosive Rheumatoid Arthritis and Poor Prognostic Factors
See more of: ACR Abstract Submission ACR Concurrent Abstract Session
<< Previous Session Level | Next Session Level >>